The potential importance of detection of neovascular age-related macular degeneration when visual acuity is relatively good

Allen C. Ho, Thomas A Albini, David M. Brown, David S. Boyer, Carl D. Regillo, Jeffrey S. Heier

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

The advent of anti-vascular endothelial growth factor treatment has changed the prognosis for patients with neovascular age-related macular degeneration (nvAMD). The ability to stabilize or improve vision with these treatments is a major step in enabling patients to continue to function at the highest possible level. Many studies have demonstrated that the better the visual acuity (VA) is at the time of treatment initiation, the higher the likelihood that VA will be better during at least the following 2 years; as such, detection of nvAMD when VA is relatively good is important. Data on the VA of patients with intermediate AMD and VA at the time of nvAMD diagnosis suggest that patients are typically losing an average of 3 to 5 lines of vision and possibly more between the time that intermediate AMD progresses to nvAMD and the diagnosis of nvAMD is made. The average patient may have nvAMD for 6 to 12 months before diagnosis and treatment initiation. Current efforts in management of nvAMD are primarily aimed at optimizing anti-vascular endothelial growth factor treatments that have the potential to improve VA outcomes by amagnitude of letters. Additional tools or other efforts to identify patients with nvAMD before substantial vision loss has occurred may reduce the amount of visual loss sustained with anti-vascular endothelial growth factor therapy, and have the potential to improve VA outcomes substantially.

Original languageEnglish (US)
Pages (from-to)268-273
Number of pages6
JournalJAMA Ophthalmology
Volume135
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Macular Degeneration
Visual Acuity
Vascular Endothelial Growth Factor A
Therapeutics
Aptitude

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The potential importance of detection of neovascular age-related macular degeneration when visual acuity is relatively good. / Ho, Allen C.; Albini, Thomas A; Brown, David M.; Boyer, David S.; Regillo, Carl D.; Heier, Jeffrey S.

In: JAMA Ophthalmology, Vol. 135, No. 3, 01.03.2017, p. 268-273.

Research output: Contribution to journalReview article

Ho, Allen C. ; Albini, Thomas A ; Brown, David M. ; Boyer, David S. ; Regillo, Carl D. ; Heier, Jeffrey S. / The potential importance of detection of neovascular age-related macular degeneration when visual acuity is relatively good. In: JAMA Ophthalmology. 2017 ; Vol. 135, No. 3. pp. 268-273.
@article{d92019f4e88547a08868dfe6351ec438,
title = "The potential importance of detection of neovascular age-related macular degeneration when visual acuity is relatively good",
abstract = "The advent of anti-vascular endothelial growth factor treatment has changed the prognosis for patients with neovascular age-related macular degeneration (nvAMD). The ability to stabilize or improve vision with these treatments is a major step in enabling patients to continue to function at the highest possible level. Many studies have demonstrated that the better the visual acuity (VA) is at the time of treatment initiation, the higher the likelihood that VA will be better during at least the following 2 years; as such, detection of nvAMD when VA is relatively good is important. Data on the VA of patients with intermediate AMD and VA at the time of nvAMD diagnosis suggest that patients are typically losing an average of 3 to 5 lines of vision and possibly more between the time that intermediate AMD progresses to nvAMD and the diagnosis of nvAMD is made. The average patient may have nvAMD for 6 to 12 months before diagnosis and treatment initiation. Current efforts in management of nvAMD are primarily aimed at optimizing anti-vascular endothelial growth factor treatments that have the potential to improve VA outcomes by amagnitude of letters. Additional tools or other efforts to identify patients with nvAMD before substantial vision loss has occurred may reduce the amount of visual loss sustained with anti-vascular endothelial growth factor therapy, and have the potential to improve VA outcomes substantially.",
author = "Ho, {Allen C.} and Albini, {Thomas A} and Brown, {David M.} and Boyer, {David S.} and Regillo, {Carl D.} and Heier, {Jeffrey S.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1001/jamaophthalmol.2016.5314",
language = "English (US)",
volume = "135",
pages = "268--273",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - The potential importance of detection of neovascular age-related macular degeneration when visual acuity is relatively good

AU - Ho, Allen C.

AU - Albini, Thomas A

AU - Brown, David M.

AU - Boyer, David S.

AU - Regillo, Carl D.

AU - Heier, Jeffrey S.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The advent of anti-vascular endothelial growth factor treatment has changed the prognosis for patients with neovascular age-related macular degeneration (nvAMD). The ability to stabilize or improve vision with these treatments is a major step in enabling patients to continue to function at the highest possible level. Many studies have demonstrated that the better the visual acuity (VA) is at the time of treatment initiation, the higher the likelihood that VA will be better during at least the following 2 years; as such, detection of nvAMD when VA is relatively good is important. Data on the VA of patients with intermediate AMD and VA at the time of nvAMD diagnosis suggest that patients are typically losing an average of 3 to 5 lines of vision and possibly more between the time that intermediate AMD progresses to nvAMD and the diagnosis of nvAMD is made. The average patient may have nvAMD for 6 to 12 months before diagnosis and treatment initiation. Current efforts in management of nvAMD are primarily aimed at optimizing anti-vascular endothelial growth factor treatments that have the potential to improve VA outcomes by amagnitude of letters. Additional tools or other efforts to identify patients with nvAMD before substantial vision loss has occurred may reduce the amount of visual loss sustained with anti-vascular endothelial growth factor therapy, and have the potential to improve VA outcomes substantially.

AB - The advent of anti-vascular endothelial growth factor treatment has changed the prognosis for patients with neovascular age-related macular degeneration (nvAMD). The ability to stabilize or improve vision with these treatments is a major step in enabling patients to continue to function at the highest possible level. Many studies have demonstrated that the better the visual acuity (VA) is at the time of treatment initiation, the higher the likelihood that VA will be better during at least the following 2 years; as such, detection of nvAMD when VA is relatively good is important. Data on the VA of patients with intermediate AMD and VA at the time of nvAMD diagnosis suggest that patients are typically losing an average of 3 to 5 lines of vision and possibly more between the time that intermediate AMD progresses to nvAMD and the diagnosis of nvAMD is made. The average patient may have nvAMD for 6 to 12 months before diagnosis and treatment initiation. Current efforts in management of nvAMD are primarily aimed at optimizing anti-vascular endothelial growth factor treatments that have the potential to improve VA outcomes by amagnitude of letters. Additional tools or other efforts to identify patients with nvAMD before substantial vision loss has occurred may reduce the amount of visual loss sustained with anti-vascular endothelial growth factor therapy, and have the potential to improve VA outcomes substantially.

UR - http://www.scopus.com/inward/record.url?scp=85015229853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015229853&partnerID=8YFLogxK

U2 - 10.1001/jamaophthalmol.2016.5314

DO - 10.1001/jamaophthalmol.2016.5314

M3 - Review article

C2 - 28114653

AN - SCOPUS:85015229853

VL - 135

SP - 268

EP - 273

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 3

ER -